Differential response to donepezil in MRI subtypes of mild cognitive impairment

© The Author(s) 2023, corrected publication 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original...

Descripción completa

Detalles Bibliográficos
Autores: Diaz-Galván, Patricia, Lorenzon, Giulia, Mohanty, Rosaleena, Mårtensson, Gustav, Cavedo, Enrica, Lista, Simone, Vergallo, Andrea, Kantarci, Kejal, Hampel, Harald, Dubois, Bruno, Grothe, Michel J., Ferreira, Daniel, Westman, Eric
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/350111
Acceso en línea:http://hdl.handle.net/10261/350111
Access Level:acceso abierto
Palabra clave:Randomized controlled trial
Donepezil
Mild cognitive impairment
Heterogeneity
Subtypes
Alzheimer’s disease
Precision medicine
id ES_df98e52e05f375e59d34a997db2f8288
oai_identifier_str oai:digital.csic.es:10261/350111
network_acronym_str ES
network_name_str España
repository_id_str
dc.title.none.fl_str_mv Differential response to donepezil in MRI subtypes of mild cognitive impairment
title Differential response to donepezil in MRI subtypes of mild cognitive impairment
spellingShingle Differential response to donepezil in MRI subtypes of mild cognitive impairment
Diaz-Galván, Patricia
Randomized controlled trial
Donepezil
Mild cognitive impairment
Heterogeneity
Subtypes
Alzheimer’s disease
Precision medicine
title_short Differential response to donepezil in MRI subtypes of mild cognitive impairment
title_full Differential response to donepezil in MRI subtypes of mild cognitive impairment
title_fullStr Differential response to donepezil in MRI subtypes of mild cognitive impairment
title_full_unstemmed Differential response to donepezil in MRI subtypes of mild cognitive impairment
title_sort Differential response to donepezil in MRI subtypes of mild cognitive impairment
dc.creator.none.fl_str_mv Diaz-Galván, Patricia
Lorenzon, Giulia
Mohanty, Rosaleena
Mårtensson, Gustav
Cavedo, Enrica
Lista, Simone
Vergallo, Andrea
Kantarci, Kejal
Hampel, Harald
Dubois, Bruno
Grothe, Michel J.
Ferreira, Daniel
Westman, Eric
author Diaz-Galván, Patricia
author_facet Diaz-Galván, Patricia
Lorenzon, Giulia
Mohanty, Rosaleena
Mårtensson, Gustav
Cavedo, Enrica
Lista, Simone
Vergallo, Andrea
Kantarci, Kejal
Hampel, Harald
Dubois, Bruno
Grothe, Michel J.
Ferreira, Daniel
Westman, Eric
author_role author
author2 Lorenzon, Giulia
Mohanty, Rosaleena
Mårtensson, Gustav
Cavedo, Enrica
Lista, Simone
Vergallo, Andrea
Kantarci, Kejal
Hampel, Harald
Dubois, Bruno
Grothe, Michel J.
Ferreira, Daniel
Westman, Eric
author2_role author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Karolinska Institute
Swedish Foundation for Strategic Research
Swedish Research Council
Stockholm County Council
Center for Innovative Medicine (Sweden)
Swedish Alzheimer Foundation
Swedish Brain Foundation
King Gustaf V and Queen Victoria's Foundation
Dementia Foundation
Olle Engkvist Foundation
Stella Birgitta Hedvig Westerberg
Gamla Tjänarinnor Foundation
Gun and Bertil Stohnes Foundation
Instituto de Salud Carlos III
National Institutes of Health (US)
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv Randomized controlled trial
Donepezil
Mild cognitive impairment
Heterogeneity
Subtypes
Alzheimer’s disease
Precision medicine
topic Randomized controlled trial
Donepezil
Mild cognitive impairment
Heterogeneity
Subtypes
Alzheimer’s disease
Precision medicine
description © The Author(s) 2023, corrected publication 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
publishDate 2023
dc.date.none.fl_str_mv 2023
2024
2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/350111
url http://hdl.handle.net/10261/350111
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv #PLACEHOLDER_PARENT_METADATA_VALUE#
info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/PI20%2F00613
https://doi.org/10.1186/s13195-023-01253-2
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Springer Nature
publisher.none.fl_str_mv Springer Nature
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869422078369726464
spelling Differential response to donepezil in MRI subtypes of mild cognitive impairmentDiaz-Galván, PatriciaLorenzon, GiuliaMohanty, RosaleenaMårtensson, GustavCavedo, EnricaLista, SimoneVergallo, AndreaKantarci, KejalHampel, HaraldDubois, BrunoGrothe, Michel J.Ferreira, DanielWestman, EricRandomized controlled trialDonepezilMild cognitive impairmentHeterogeneitySubtypesAlzheimer’s diseasePrecision medicine© The Author(s) 2023, corrected publication 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.[Background] Donepezil is an approved therapy for the treatment of Alzheimer’s disease (AD). Results across clinical trials have been inconsistent, which may be explained by design-methodological issues, the pathophysiological heterogeneity of AD, and diversity of included study participants. We investigated whether response to donepezil differs in mild cognitive impaired (MCI) individuals demonstrating different magnetic resonance imaging (MRI) subtypes.[Methods] From the Hippocampus Study double-blind, randomized clinical trial, we included 173 MCI individuals (donepezil = 83; placebo = 90) with structural MRI data, at baseline and at clinical follow-up assessments (6–12-month). Efficacy outcomes were the annualized percentage change (APC) in hippocampal, ventricular, and total grey matter volumes, as well as in the AD cortical thickness signature. Participants were classified into MRI subtypes as typical AD, limbic-predominant, hippocampal-sparing, or minimal atrophy at baseline. We primarily applied a subtyping approach based on continuous scale of two subtyping dimensions. We also used the conventional categorical subtyping approach for comparison.[Results] Donepezil-treated MCI individuals showed slower atrophy rates compared to the placebo group, but only if they belonged to the minimal atrophy or hippocampal-sparing subtypes. Importantly, only the continuous subtyping approach, but not the conventional categorical approach, captured this differential response.[Conclusions] Our data suggest that individuals with MCI, with hippocampal-sparing or minimal atrophy subtype, may have improved benefit from donepezil, as compared with MCI individuals with typical or limbic-predominant patterns of atrophy. The newly proposed continuous subtyping approach may have advantages compared to the conventional categorical approach. Future research is warranted to demonstrate the potential of subtype stratification for disease prognosis and response to treatment.[Trial registration] ClinicalTrial.gov NCT00403520. Submission Date: November 21, 2006.Open access funding provided by Karolinska Institute. This study was funded by the Swedish Foundation for Strategic Research (SSF); the Strategic Research Programme in Neuroscience at Karolinska Institutet (StratNeuro); the Swedish Research Council (VR); the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet; Center for Innovative Medicine (CIMED); the Swedish Alzheimer Foundation; the Swedish Brain Foundation; King Gustaf V:s and Queen Victorias Foundation; Demensfonden; Stiftelsen Olle Engkvist Byggmästare; Birgitta och Sten Westerberg; Foundation for Geriatric Diseases at Karolinska Institutet; Loo och Hans Ostermans stiftelse för medicinsk forskning; Stiftelsen För Gamla Tjänarinnor; Gun & Bertil Stohnes Stiftelse. MJG is supported by the “Miguel Servet” programme [CP19/00031] and a research grant [PI20/00613] of the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER), National Institutes of Health, USA (U01 NS100620, P50 AG16574).Peer reviewedSpringer NatureKarolinska InstituteSwedish Foundation for Strategic ResearchSwedish Research CouncilStockholm County CouncilCenter for Innovative Medicine (Sweden)Swedish Alzheimer FoundationSwedish Brain FoundationKing Gustaf V and Queen Victoria's FoundationDementia FoundationOlle Engkvist FoundationStella Birgitta Hedvig WesterbergGamla Tjänarinnor FoundationGun and Bertil Stohnes FoundationInstituto de Salud Carlos IIINational Institutes of Health (US)Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]202420242023info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://hdl.handle.net/10261/350111reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Inglés#PLACEHOLDER_PARENT_METADATA_VALUE#info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/PI20%2F00613https://doi.org/10.1186/s13195-023-01253-2Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/3501112026-05-22T06:33:51Z
score 15,812429

Similares en LA Referencia